Dose-Escalated Image-Guided Radiotherapy (IGRT) With Magnetic Resonance Imaging (MRI)-Based Target Definition for Locally and Regionally Advanced Prostate Cancer: A Phase II Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07900555

Title field or adapter rule

{'original_value': 'Dose-Escalated Image-Guided Radiotherapy (IGRT) With Magnetic Resonance Imaging (MRI)-Based Target Definition for Locally and Regionally Advanced Prostate Cancer: A Phase II Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:28.527633+00:00

Published At

2026-10-30T00:00:00+00:00

Record Updated At

2026-10-30

Source Retrieved At

2026-10-31T22:18:05.512861+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Prostate Cancer", "Prostate Cancer Locally Advanced", "Prostatic Neoplams"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07900555"

protocolSection.identificationModule.officialTitle

"Dose-Escalated Image-Guided Radiotherapy (IGRT) With Magnetic Resonance Imaging (MRI)-Based Target Definition for Locally and Regionally Advanced Prostate Cancer: A Phase II Study"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Prostate Cancer (protocolSection.conditionsModule.conditions)
• Prostate Cancer Locally Advanced (protocolSection.conditionsModule.conditions)
• Prostatic Neoplams (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Hypofractionated focal boost radiotherapy'], 'description': 'Image-guided IMRT in 25 fractions: 2.9 Gy/fraction (72.5 Gy) to the MRI-defined tumour, 2.4 Gy/fraction (60 Gy) to the uninvolved prostate and seminal vesicles, and 2.0 Gy/fraction (50 Gy) to the elective pelvic lymph nodes, with a boost of 2.4 Gy/fraction (60 Gy) to involved lymph nodes in node-positive patients.', 'name': 'Hypofractionated IMRT with focal simultaneous integrated boost and elective pelvic irradiation', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Hypofractionated focal boost radiotherapy'], 'description': 'Androgen deprivation therapy started approximately 3 months before radiotherapy: an luteinizing hormone-releasing hormone (LHRH) analogue with at least 4 weeks of antiandrogen, or alternatively an LHRH antagonist. Planned duration 18 months if clinically tolerated. Antiandrogen monotherapy was an option in case of poor tolerance of the LHRH analogue.', 'name': 'Androgen Deprivation Therapy (ADT)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Androgen Deprivation Therapy (ADT) (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.